Of interest, CXCR3 ligands, CXCL9 and CXCL10, are increased in the serum of Jo1+ and SRP+ myositis patients (59), and CXCL10 is a validated disease activity biomarker for juvenile dermatomyositis (60). This evidence concerns the gene CXCL10 and myositis disease.